Hypnos SWS-001

Hypnos Sws-001

A novel small-molecule series designed to restore slow-wave sleep architecture not sedation as a route to sustained glymphatic clearance in early neurodegeneration.

Description

A novel small-molecule series designed to restore slow-wave sleep architecture not sedation as a route to sustained glymphatic clearance in early neurodegeneration.

Team

0xb5a9d…87d23

Owner

Project Score

Updated Aug 21, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Hypnos Sws-001

A novel small-molecule series designed to restore slow-wave sleep architecture not sedation as a route to sustained glymphatic clearance in early neurodegeneration.

Description

A novel small-molecule series designed to restore slow-wave sleep architecture not sedation as a route to sustained glymphatic clearance in early neurodegeneration.

Team

0xb5a9d…87d23

Owner

Project Score

Updated Aug 21, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project explicitly states that no experimental laboratory work has been conducted — no synthesis, no biological assays, and no in vivo studies. All work is purely computational and analytical (physicochemical predictions, molecular docking, virtual library enumeration, in silico ADMET profiling). The project self-identifies as TRL 2 but under the classification framework used here, TRL 2 requires the presence of empirical experimental data, which is entirely absent. The concept is well-formulated with a biologically plausible hypothesis grounded in the psilocybin/psilocin prodrug precedent, but it remains unvalidated by any wet-lab experimentation.

Assessment

Low Confidence

RecommendationSUPPLEMENT

Total Score3.60

Overall Assessment

The bufotenine prodrug project scores a final weighted score of 3.60 out of 5.00, placing it in the upper-moderate range for a TRL 1-level evaluation (noting the project self-identifies as TRL 2 but is being assessed against TRL 1 criteria as specified). The strongest dimension is Therapeutic Relevance (4/5, weighted 2.40), reflecting a scientifically well-reasoned mechanism with strong biological precedent from the psilocybin prodrug paradigm and clear targeting of validated psychiatric disease biology. The score is held back from a 5 by the explicitly acknowledged core assumption risk — that bufotenine's weak psychoactivity is pharmacokinetic rather than pharmacodynamic — which remains entirely unvalidated at this computational stage. Intellectual Property scores moderately (3/5, weighted 0.75), reflecting genuine novelty in the specific bufotenine prodrug chemical space but tempered by a crowded and fast-moving psychedelic patent landscape and an FTO scan that has not yet been completed. Therapeutic Optionality also scores moderately (3/5, weighted 0.45), as the platform offers tunability across psychiatric indications and dosing paradigms but remains fundamentally anchored to the 5-HT2A/tryptamine axis with limited diversification potential and significant regulatory constraints from controlled-substance scheduling. Overall, this is a well-conceived early-stage project with rigorous self-awareness of its risks and limitations, clear go/no-go gates, and a logical path to experimental validation. The primary value drivers for advancement will be (1) confirming the pharmacokinetic hypothesis at TRL 3, (2) establishing a defensible IP position through WP6, and (3) demonstrating 5-HT2A/5-HT2B selectivity separation in wet-lab assays.

Weighted Score

Therapeutic Relevance

The mechanism is scientifically plausible and well-grounded. The prodrug approach directly mirrors the validated psilocybin→psilocin precedent, and the rationale for masking the 5-OH to improve CNS penetration is physicochemically sound. The project targets a biologically relevant disease mechanism (5-HT2A agonism for psychiatric indications) with strong clinical precedent from psilocybin trials. However, the project explicitly acknowledges a critical unvalidated assumption — that bufotenine's weak psychoactivity is pharmacokinetic rather than pharmacodynamic — which, if wrong, invalidates the entire premise. The 5-HT2B liability (valvulopathy risk) is a real concern, though the team has built in early triage gates. The two high-severity risks (BBB predictor accuracy for ionizable species and hydrolysis rate uncertainty) temper confidence. Score of 4 rather than 5 because the core assumption remains untested and the computational-only stage means no experimental confirmation of the mechanism yet exists.

Therapeutic Optionality

The concept has moderate flexibility. The prodrug platform could theoretically be applied to other phenolic tryptamines beyond bufotenine, and the promoiety design space (esters, carbamates, phosphates, amino-acid conjugates) offers tunability for onset/duration across different clinical use cases (e.g., acute psychedelic-assisted therapy vs. sub-psychedelic microdosing). The psychiatric indication space itself is broad (depression, PTSD, anxiety, addiction). However, the concept is fundamentally tethered to the 5-HT2A agonist mechanism and the tryptamine scaffold, limiting diversification into wholly different therapeutic areas. The controlled-substance regulatory burden further constrains optionality. The project does not articulate applications beyond psychiatric indications. A score of 3 reflects meaningful but bounded therapeutic flexibility.

Intellectual Property

The concept is novel enough to potentially support patent claims — specific 5-position prodrugs of bufotenine with defined promoiety classes represent a distinct chemical matter space. However, the project itself flags the IP landscape as crowded, with the psilocybin analog space heavily patented and the psychedelic IP landscape moving quickly. The general concept of phenolic prodrugs on tryptamine scaffolds is well-established (psilocybin being the archetype), which raises prior art concerns for broader claims. WP6 (FTO scan) has not yet been executed, so the actual freedom-to-operate position is unknown — this is a significant gap. The project wisely plans to run WP6 early, but until results are in hand, IP risk remains unquantified. Specific novel structures may be patentable, but method-of-treatment and platform claims face headwinds from existing art. Score of 3 reflects genuine novelty in the specific chemical space offset by a crowded landscape and unresolved FTO status.